Levulan Patent Expiration

Levulan is a drug owned by Dusa Pharmaceuticals Inc. It is protected by 11 US drug patents filed from 2013 to 2023. Out of these, 5 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 12, 2038. Details of Levulan's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5079262 Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
Sep, 2013

(10 years ago)

Expired
US5954703 Method and apparatus for applying 5-aminolevulinic acid
Oct, 2017

(6 years ago)

Expired
US8216289 Illuminator for photodynamic therapy
May, 2018

(6 years ago)

Expired
US6709446 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
May, 2018

(6 years ago)

Expired
US8758418 Illuminator for photodynamic therapy
May, 2018

(6 years ago)

Expired
US7723910 Method of photodynamically diagnosing or treating a contoured surface
Jun, 2019

(5 years ago)

Expired
US11135293 Methods for photodynamic therapy
Jan, 2038

(13 years from now)

Active
US11690914 Methods for photodynamic therapy
Jan, 2038

(13 years from now)

Active
US11077192 Methods for photodynamic therapy
Jan, 2038

(13 years from now)

Active
US10357567 Methods for photodynamic therapy
Jan, 2038

(13 years from now)

Active
US11571478 Methods for photodynamic therapy
Jan, 2038

(13 years from now)

Active


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Levulan and ongoing litigations to help you estimate the early arrival of Levulan generic.

Levulan's Litigations

Levulan has been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 19, 2021, against patent number US10357567. The petitioner Biofrontera Inc. et al., challenged the validity or infringement of this patent, with DUSA Pharmaceuticals, Inc. et al. as the respondent. Click below to track the latest information on how companies are challenging Levulan's patents.


Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10357567 October, 2021 Terminated-Dismissed DUSA Pharmaceuticals, Inc. et al. Biofrontera Inc. et al.


FDA has granted some exclusivities to Levulan. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Levulan, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Levulan.

Exclusivity Information

Levulan holds 2 exclusivities. All of its exclusivities have expired in 2021. Details of Levulan's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Mar 12, 2013
New Indication(I-766) Mar 09, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Levulan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Levulan's family patents as well as insights into ongoing legal events on those patents.

Levulan's family patents

Levulan has patent protection in a total of 4 countries. It's US patent count contributes only to 38.5% of its total global patent coverage. Click below to unlock the full patent family tree for Levulan.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Levulan's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 12, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Levulan Generics:

There are no approved generic versions for Levulan as of now.





About Levulan

Levulan is a drug owned by Dusa Pharmaceuticals Inc. It is used for treating actinic keratoses on the upper extremities, face, and scalp through photodynamic therapy. Levulan uses Aminolevulinic Acid Hydrochloride as an active ingredient. Levulan was launched by Dusa in 1999.

Market Authorisation Date:

Levulan was approved by FDA for market use on 03 December, 1999.

Active Ingredient:

Levulan uses Aminolevulinic Acid Hydrochloride as the active ingredient. Check out other Drugs and Companies using Aminolevulinic Acid Hydrochloride ingredient

Treatment:

Levulan is used for treating actinic keratoses on the upper extremities, face, and scalp through photodynamic therapy.

Dosage:

Levulan is available in solution form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
20% SOLUTION Prescription TOPICAL